Carolyn Hruban

Correction to: Nature https://doi.org/10.1038/nature14969 Published online 30 September 2015 In Extended Data Fig. 8 of this article, a micrograph shown in the left column (panel AZD) was inadvertently duplicated during figure preparation. The intended image was meant to show phospho-ERK (P-ERK) levels in a MAP2K1-mutant patient-derived xenograft (PDX) exposed to the MEK inhibitor AZD6244 (AZD). However, this image was accidentally overlaid with a micrograph from Extended Data Fig.

Abstract Determining response to therapy for patients with pancreatic cancer can be challenging. We evaluated methods for assessing therapeutic response using cell-free DNA (cfDNA) in plasma from patients with metastatic pancreatic cancer in the CheckPAC trial (NCT02866383). Patients were evaluated before and after initiation of therapy using tumor-informed plasma whole-genome sequencing (WGMAF) and tumor-independent genome-wide cfDNA fragmentation profiles and repeat landscapes (ARTEMIS-DELFI).

A new study led by researchers at Johns Hopkins Kimmel Cancer Center is showing a novel blood test can detect the presence of lung cancer with over 90 percent accuracy. The test uses artificial intelligence to identify abnormal patterns in fragments of cancer DNA circulating in a patient’s bloodstream. This cancer-detecting blood test focuses on tiny traces of cancer DNA that can be found in a person’s bloodstream.